All companies
Visit website
SOLAXA PBC
OperatingSolaxa Inc.
Healthcare · Technology · Founded 2021
Restoring people's lives suffering from nerve dysfuncion with FDA approved drug
Valuation cap ⓘ
$15.0M
As of Apr 2024 · from SOLAXA PBC Future Equity SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$0
Across 1 round since 2023
Latest share price
$1.00
SOLAXA PBC Future Equity SAFE 1 offering price
Financials
FY2021–FY2022 · from SEC filings · hover any figure for its source$0
−$18K
2021
$0
−$200K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$17,652
-$200,342
Taxes paid
$0
$1,550
Balance sheet
Cash
$55,026
$287
Accounts receivable
$0
$0
Total assets
$72,358
$319,840
Short-term debt
$0
$302,262
Long-term debt
$0
$84,062
Total liabilities
$0
$386,324
Other
Headcount
—
3
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$15.0M
Valuation cap
SOLAXA PBC Future Equity SAFE 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised — / $1.2MValuation cap $15M
Reg CF annual-report compliance
Not obligated
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001975400Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.